Analyst Price Targets — ARQT
| Date | Analyst | Firm | Target | Price @ Post | Source | Headline |
|---|---|---|---|---|---|---|
| August 6, 2026 11:34 am | — | Morgan Stanley | $38.00 | $27.10 | TheFly | Arcutis Biotherapeutics price target raised to $38 from $34 at Morgan Stanley |
| August 6, 2026 10:44 am | Seamus Fernandez | Guggenheim | $38.00 | $27.10 | StreetInsider | Arcutis Biotherapeutics Inc. (ARQT) PT Raised to $38 at Guggenheim |
| February 26, 2026 11:40 am | Doug Tsao | H.C. Wainwright | $34.00 | $27.01 | StreetInsider | Arcutis Biotherapeutics Inc. (ARQT) PT Raised to $34 at H.C. Wainwright |
| November 28, 2025 11:32 am | Uy Ear | Mizuho Securities | $37.00 | $30.96 | StreetInsider | Arcutis Biotherapeutics Inc. (ARQT) PT Raised to $37 at Mizuho |
| October 30, 2025 11:29 am | Richard Law | Goldman Sachs | $29.00 | $25.41 | TheFly | Arcutis Biotherapeutics price target raised to $29 from $19 at Goldman Sachs |
| October 29, 2025 10:20 am | Douglas Tsao | H.C. Wainwright | $30.00 | $24.95 | TheFly | Arcutis Biotherapeutics price target raised to $30 from $22 at H.C. Wainwright |
| October 29, 2025 10:11 am | Uy Ear | Mizuho Securities | $32.00 | $24.95 | StreetInsider | Arcutis Biotherapeutics Inc. (ARQT) PT Raised to $32 at Mizuho |
| March 11, 2025 5:59 pm | — | Jefferies | $19.00 | $15.49 | TheFly | Arcutis Biotherapeutics price target raised to $19 from $16 at Jefferies |
| December 30, 2024 11:08 am | Douglas Tsao | H.C. Wainwright | $19.00 | $14.20 | TheFly | Arcutis Biotherapeutics initiated with a Buy at H.C. Wainwright |
| May 15, 2024 7:15 am | Serge Belanger | Needham | $18.00 | $8.13 | StreetInsider | Arcutis Biotherapeutics Inc. (ARQT) PT Raised to $18 at Needham |
Latest News for ARQT
Arcutis raises its 2026 revenue guidance as Zoryve gains momentum, expands into younger patients and advances potential new indications.
Halozyme, Repligen, Iovance, Arcutis and Precigen have been highlighted in this Industry Outlook article.
Bamco Inc. NY acquired a new position in shares of Arcutis Biotherapeutics, Inc. (NASDAQ: ARQT) during the second quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund acquired 1,253,120 shares of the company's stock, valued at approximately $32,857,000. Bamco Inc. NY owned
New drug approvals and encouraging pipeline progress should maintain momentum in the Zacks Biomedical and Genetics industry despite the uncertain macroeconomic environment. A strong portfolio and solid pipeline progress position HALO, RGEN, IOVA, ARQT and PGEN in this volatile sector.
Deutsche Bank AG bought a new stake in shares of Arcutis Biotherapeutics, Inc. (NASDAQ: ARQT) during the undefined quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor bought 382,682 shares of the company's stock, valued at approximately $10,034,000. Deutsche Bank AG owned approximately 0.31% of Arcutis
🧮 Earnings Move Analyzer
Insider Trading
Insider Trading
| Name | Role | Date | Type | Shares | Price | Form | Link |
|---|
Senate Trading
No Senate trades found for ARQT.
U.S. House Trading
House Trades Disclosures
| Name | Transaction Date | Type | Asset | Amount | Link |
|---|
Options Chain
Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.